Hormone Receptor Positive Tumor Clinical Trials

31 clinical trials for Hormone Receptor Positive Tumor across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — RECRUITING · PHASE3
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors — RECRUITING · PHASE1
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy — RECRUITING · PHASE2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer — RECRUITING · PHASE2
• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer — RECRUITING · PHASE2
• A Study of the TheraBionic P1 Device in Breast Cancer — RECRUITING · NA
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer — RECRUITING · PHASE1
• Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer — RECRUITING
• SNF Platform Study of HR+/ HER2-advanced Breast Cancer — RECRUITING · PHASE2
• A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer — NOT_YET_RECRUITING · NA
• Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer — ACTIVE_NOT_RECRUITING
• Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer — COMPLETED · PHASE2
• First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors — COMPLETED · PHASE1
• Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer — COMPLETED · NA
• Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer — COMPLETED · PHASE2
• Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer — COMPLETED · PHASE1
• Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) — OTHER · PHASE1
• A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. — OTHER · PHASE2
• PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) — COMPLETED · PHASE2
• Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant — COMPLETED · PHASE2
• Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line — COMPLETED · PHASE3
• Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer — TERMINATED · PHASE2
• Dose EScalation Induction of EvERolimus — COMPLETED · PHASE2
• Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer — OTHER · PHASE1
• Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer — COMPLETED · PHASE2
• Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) — COMPLETED · NA
• Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer — OTHER · PHASE2
• Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC — OTHER · PHASE2
• Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer — OTHER · PHASE3

Refine this search